These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Researchers are rethinking role of AZT in drug therapy. AIDS Policy Law; 1995 Oct 06; 10(18):11. PubMed ID: 11362821 [Abstract] [Full Text] [Related]
23. Triple therapy in previously untreated patients reduces viral load below limit of detection. AIDS Patient Care STDS; 1996 Oct 06; 10(5):308-9. PubMed ID: 11361526 [No Abstract] [Full Text] [Related]
24. Review of viral load and combination therapy data from 35th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Bray JM. STEP Perspect; 1995 Oct 06; 7(3):10-1. PubMed ID: 11362980 [Abstract] [Full Text] [Related]
25. AZT studies reinforce benefits of combination. AIDS Alert; 1995 Jan 06; 10(1):11-2. PubMed ID: 11362167 [Abstract] [Full Text] [Related]
26. 3TC/AZT: just another combination. GMHC Treat Issues; 1995 Dec 06; 9(12):2. PubMed ID: 11362997 [Abstract] [Full Text] [Related]
27. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A. Antivir Ther; 2005 Dec 06; 10(5):605-14. PubMed ID: 16152754 [Abstract] [Full Text] [Related]
28. Back to the nukes. Smart T. GMHC Treat Issues; 1996 Feb 06; 10(2):6-7. PubMed ID: 11363383 [Abstract] [Full Text] [Related]
29. AZT delta study: major European/Australian study finds combinations better than AZT alone. King E. AIDS Treat News; 1995 Oct 06; (no 232):3-4. PubMed ID: 11362876 [Abstract] [Full Text] [Related]
30. FDA approves first new class of HIV drugs. Food and Drug Administration. AIDS Alert; 1996 Aug 06; 11(8):89. PubMed ID: 11363655 [Abstract] [Full Text] [Related]
31. ddI plus d4T. James JS. AIDS Treat News; 1996 Sep 06; (No 254):4. PubMed ID: 11363818 [Abstract] [Full Text] [Related]
32. Another option for less than 50 T4 cells. Treat Rev; 1995 Sep 06; (no 19):3. PubMed ID: 11362755 [Abstract] [Full Text] [Related]
33. Benefits of combination therapy confirmed. Cheng B. PI Perspect; 1995 Dec 06; (no 17):3-4. PubMed ID: 11363111 [Abstract] [Full Text] [Related]
34. Antiretroviral drug resistance. Japour AJ. AIDS Clin Care; 1995 Aug 06; 7(8):63-5, 67. PubMed ID: 11362787 [Abstract] [Full Text] [Related]
35. To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour. Coombs R, Cotton D, Hammer S, Saag M, van der Horst C. AIDS Clin Care; 1996 Jan 06; 8(1):1-4. PubMed ID: 11363056 [Abstract] [Full Text] [Related]
36. Closing the circle on HIV--or not. Mascolini M. J Int Assoc Physicians AIDS Care; 1995 Oct 06; 1(9):10-4, 17-29 contd. PubMed ID: 11362964 [Abstract] [Full Text] [Related]
37. Update on HIV protease inhibitors. Vella S. AIDS Clin Care; 1995 Oct 06; 7(10):79-82, 88. PubMed ID: 11362832 [Abstract] [Full Text] [Related]
38. Study results at a glance. AIDS Alert; 1995 Nov 06; 10(11):134. PubMed ID: 11362922 [Abstract] [Full Text] [Related]
39. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive. James JS. AIDS Treat News; 1995 Dec 22; (no 237):3. PubMed ID: 11363075 [Abstract] [Full Text] [Related]
40. Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV. Crowe S, Cooper DA, Chambers DE. Med J Aust; 1996 Mar 04; 164(5):290-5. PubMed ID: 8628165 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]